Carvedilol for treating heart failure, post-heart attack dysfunction, and hypertension

Carvedilol tablets are prescription heart medicines used primarily to treat mild-to-severe chronic heart failure, reduce the risk of death after a heart attack in patients with weakened heart function, and manage essential hypertension. It is typically taken together with other heart medications and requires individualized dosing under medical supervision.

Carvedilol tablets are approved for the following uses:

• Chronic heart failure: Treatment of mild-to-severe heart failure caused by ischemic or cardiomyopathic heart disease, often alongside diuretics, ACE inhibitors, and digitalis, to improve survival and reduce hospitalizations.
• Left ventricular dysfunction after myocardial infarction: Used in clinically stable patients who survived an acute heart attack and have a left ventricular ejection fraction of 40% or less, with or without heart failure symptoms, to reduce cardiovascular death.
• Hypertension: Management of essential high blood pressure alone or in combination with other drugs such as thiazide diuretics.

Carvedilol

Carvedilol works by blocking both beta-adrenergic and alpha-1 adrenergic receptors, which helps slow heart rate, decrease blood pressure, and reduce heart workload. This dual action improves heart function and reduces damaging effects after heart attacks or in heart failure, while lowering blood pressure in hypertension.

Dosing must be individualized and closely monitored by a healthcare provider.

Heart failure

• Start with 3.125 mg twice daily for 2 weeks.
• If tolerated, increase gradually every 2 weeks to 6.25 mg, then 12.5 mg, then 25 mg twice daily.
• Maximum doses up to 50 mg twice daily in patients over 85 kg have been used.
• Take with food to reduce side effects like dizziness.
• Monitor for fluid retention and adjust diuretics accordingly.
• Reduce dose if heart rate drops below 55 bpm.

Post-myocardial infarction left ventricular dysfunction

• Start at 6.25 mg twice daily once patient is stable and fluid retention minimized.
• Increase after 3 to 10 days to 12.5 mg twice daily, then up to 25 mg twice daily as tolerated.
• Lower starting dose (3.125 mg twice daily) or slower titration may be needed if blood pressure or heart rate is low.

Hypertension

• Start with 6.25 mg twice daily.
• If tolerated, maintain for 7-14 days, then increase to 12.5 mg twice daily if needed.
• After another 7-14 days, may increase to 25 mg twice daily if necessary.
• Maximum total daily dose is 50 mg.

Important administration instructions

• Take Carvedilol with food to slow absorption and reduce orthostatic hypotension.
• Avoid sudden discontinuation of the drug.

• Bronchial asthma or related bronchospastic conditions due to risk of fatal asthma attacks.
• Second- or third-degree atrioventricular block and sick sinus syndrome without a pacemaker.
• Severe bradycardia without a pacemaker.
• Cardiogenic shock or decompensated heart failure requiring intravenous inotropic therapy unless stabilized.
• Severe hepatic impairment.
• History of serious hypersensitivity reactions to Carvedilol or its components.

Serious risks and precautions include:

• Do not abruptly stop Carvedilol to avoid worsening angina, heart attack, or arrhythmias; taper over 1 to 2 weeks under medical supervision.
• Monitor for bradycardia; reduce dose if pulse
• Hypotension and syncope are most common during dose initiation and up-titration; take precautions to avoid injury during this period.
• Heart failure symptoms or fluid retention may worsen initially; manage with increased diuretics and do not advance dose until stable.
• Use cautiously in patients with bronchospastic diseases; use smallest effective dose if needed.
• May mask hypoglycemia symptoms; monitor blood glucose in diabetic patients during therapy changes.
• Use caution in peripheral vascular disease due to risk of worsening symptoms.
• Monitor renal function during up-titration in patients with low blood pressure, ischemic heart disease, or renal insufficiency; discontinue if renal function worsens.
• Be alert for intraoperative floppy iris syndrome during cataract surgery in patients on alpha-1 blockers including carvedilol.
• Caution in pheochromocytoma and Prinzmetal's variant angina due to limited experience.
• Patients with severe hepatic impairment should not receive Carvedilol.

Common side effects observed include:

• Dizziness, fatigue, asthenia.
• Bradycardia, hypotension, syncope.
• Edema (generalized and dependent), weight increase.
• Gastrointestinal symptoms: diarrhea, nausea, vomiting.
• Hyperglycemia and changes in blood biochemistry such as increased BUN and hypercholesterolemia.
• Respiratory symptoms: cough, rales.
• Vision abnormalities.

Other less frequent side effects include headache, insomnia, arthralgia, peripheral edema, and rash. Discontinuation due to dizziness is reported in approximately 1.3% of heart failure patients.

Carvedilol's blood pressure lowering effect may be increased when used with diuretics, especially thiazide diuretics, causing enhanced orthostatic hypotension. It should be used cautiously with ACE inhibitors; dose adjustments and staggered timing may reduce side effects.

Information on use during pregnancy or breastfeeding is not provided in the supplied label evidence.

The label does not provide specific overdose manifestations or management instructions.